查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495982

血液診斷市場 – 2024 年至 2029 年預測

Haematology Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年血液診斷市場規模為65.83億美元，複合年成長率為6.18%，2029年將達100.12億美元。

血液學是對血液和血液相關疾病的研究。血液相關疾病和病症（例如貧血、血癌和血栓）的診斷屬於血液學診斷的範疇。在過去幾年中，此類血液疾病的盛行率一直在增加，是預計在預測期內推動血液診斷市場成長的關鍵因素之一。

此外，血液診斷技術的進步使診斷變得更加方便和高效。市場持續的技術創新預計也將在未來幾年進一步促進市場成長。此外，全球老年人口的成長正在導致患者數量的增加，這是預計在評估期間推動需求的另一個重要因素。

市場促進因素：

  • 由於血液疾病的增加，血液診斷市場預計將快速成長。

貧血、血友病、血癌和血栓等各種類型的血液疾病在全世界不斷增加。貧血是一種如此普遍的疾病，其外顯率不斷增加。根據世界銀行資料，6至59個月兒童貧血盛行率從2010年的10.4%上升至2019年的13.2%。在芬蘭，這一比例從2010年的10%上升到2019年的11.8%，在丹麥，這一比例從2010年的12.6%上升到2019年的14.5%。

此外，根據世界銀行的資料，全球育齡或15歲至59歲女性貧血盛行率已從2013年的28.5%躍升至2019年的29.9%。此外，血癌病例正在快速增加，預計將在預測期內推動血液診斷市場的成長。

根據美國癌症協會估計，2021 年美國將新增 61,090 例白血病病例。此外，同期美國的白血病發生率男性從每 10 萬人口 18 例增加到 2017 年的約 20 例，女性從每 10 萬人 10.8 例增加到 11.8 例。澳洲白血病基金會預測，血癌患者人數將從 2020 年的 11 萬人增加到 2035 年的 275,000 多人。

  • 預計老年人口的成長將推動血液學診斷的需求

過去幾年，世界老年人口持續成長，預計未來幾年將持續成長。隨著老年人口老化，貧血和白血病等血液疾病的風險增加。定期血液學評估對於早期發現和治療至關重要。

心血管疾病和糖尿病等慢性疾病也會影響血液學參數，因此血液診斷對於監測其對血液成分的影響並識別相關併發症至關重要。在美國，65歲以上人口占總人口的比例從2010年的12.98%上升到2020年的16.63%（資料來源：世界銀行）。中國也是一個老年人口快速成長的國家。

65歲以上人口將從2010年的1,080.12億增加到2020年的1,688.64億，10年間成長36%以上。在法國，65歲以上人口數從2010年的109.58億快速成長至2020年的139.86億，成長超過27%。 （圖片來源：世界銀行）

人口老化預計將持續下去，這將極大地導致患者數量的增加。預計這將在評估期間對全球血液診斷市場產生積極影響。

北美地區佔據主要市場佔有率

從地理位置來看，由於診斷中心豐富，北美地區預計將佔據主要市場佔有率。此外，先進的醫療系統使人們更容易接受血液疾病的診斷，導致該地區血液診斷市場規模龐大。

由於醫療設施的改善使更多人能夠獲得所需的醫療服務，預計北美地區將顯著成長。老年人口和總人口的增加是預計在預測期內推動該地區血液診斷市場成長的其他重要原因。

北美先進的醫療基礎設施、血液疾病的高盛行率以及慢性病盛行率的上升正在推動對先進血液診斷的需求。該地區對這些疾病的早期診斷和監測的重視正在推動對血液診斷的需求。自動分析儀和分子診斷等診斷技術的進步正在吸引醫療保健提供者投資最新的解決方案。就地檢驗也變得越來越普及，有助於市場成長。

主要發展

  • 2024 年 2 月 - Sysmex Corporation 和 CellaVision 簽訂了一項策略合作協議，透過擴展其產品組合以包含下一代細胞形態分析儀來推進血液學解決方案。雙方合作始於 20 年前的血液學領域，該領域分析紅血球、白血球和其他血球。該協議有效期至 2038 年，利用 Sysmex 在血液學領域測試工作流程效率和標準化方面的專業知識，同時最大限度地發揮與 CellaVision 數位影像處理和分析技術的協同效應。
  • 2023 年 8 月 - Abbott 的 Alinity h 系列血液檢測系統獲得 FDA 批准。作為 Alinity 診斷產品系列的一部分，該系統使實驗室能夠執行全血球計數 (CBC)。該系統包括自動血液分析儀、切片機和染色機。 Alinity h 系列描述了醫生可以用來快速有效地護理患者的廣泛測試。優點包括每小時能夠處理多達 119 個 CBC 結果、安裝空間小以及集中的結果和控制功能。
  • 2023 年 7 月 - Sysmex Europe SE 推出其實驗室血液學旗艦產品線 XR 系列。該產品線建立在其前身 XN 系列的可靠性和技術之上。列出了新資產和通量改進以滿足實驗室需求。 XR系列在日本推出，融合了全球客戶的優勢。血液學實驗室可以自動執行條碼讀取、試管分類、抹片管理和試劑管理。總裁兼執行長 Alain Baverel 表示，XR 系列是實驗室的可靠選擇，旨在繼續為血液檢測提供可靠的診斷和服務。

主要市場區隔

按測試類型

  • 血紅素
  • 血球計數
  • 血小板功能
  • 分血器
  • 其他

按最終用戶

  • 醫院和診所
  • 診斷中心
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章血液診斷市場：依測試類型

  • 介紹
  • 血紅素
  • 血球計數
  • 血小板功能
  • 分血器
  • 其他

第6章血液診斷市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 診斷中心
  • 其他

第7章血液診斷市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Bio-Rad Laboratories, Inc.
  • Boule Diagnostics AB
  • Abbott Laboratories
  • Diatron
  • Biosystems SA
  • F. Hoffmann-La Roche Ltd
  • Horiba, Ltd.
  • Erba Diagnostics Mannheim GmbH
  • Ortho Clinical Diagnostics
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
簡介目錄
Product Code: KSI061611962

The haematology diagnostics market is evaluated at USD6.583 billion for the year 2022, growing at a CAGR of 6.18% to reach the market size of USD10.012 billion by the year 2029.

Haematology is the study of blood and blood-related diseases. The diagnosis of diseases or disorders related to blood, including anemia, blood cancer, and blood clots, among others, comes under the umbrella of haematology diagnostics. The incidences of such blood disorders have been increasing over the past years and are one of the major factors anticipated to drive the haematology diagnostics market growth during the forecast period.

Furthermore, the technological advancements in haematology diagnostics have made it more convenient and efficient. The continuous innovation in the market is expected to augment the market growth further in the coming years as well. Moreover, the growing geriatric population worldwide leads to an increase in the number of patients and is another prominent factor anticipated to boost the demand during the assessment period.

Market Drivers:

  • Rising incidences of blood disorders is expected to surge the Haematology Diagnostics Market.

Various kinds of blood disorders are on the rise worldwide, including anemia, hemophilia, blood cancer, and blood clots, among others. Anemia is one such widely prevalent disorder that is increasing its pervasiveness. According to data from the World Bank, the prevalence of anemia among children aged 6-59 months has increased from 10.4% in 2010 to 13.2% in 2019. In Finland, it has increased from 10% in 2010 to 11.8% in 2019, while in Denmark, it reached 14.5% in 2019, rising from 12.6% in 2010.

Furthermore, the data from the World Bank shows that the global prevalence of anemia among women of reproductive age or women aged 15 to 59 years has jumped from 28.5% in 2013 to 29.9% in 2019. Moreover, the cases of blood cancer are increasing at a fast pace, which is expected to propel the haematology diagnostics market growth during the forecast period.

The American Cancer Society states that the estimated new cases of leukemia in the United States in 2021 will be 61,090. It also states that the incidence rate of leukemia in the U.S. has increased from 18 in 2009 to around 20 per 100,000 population in 2017 for males and from 10.8 to 11.8 for females during the same time period. The Leukaemia Foundation in Australia projects the number of blood cancer cases from 110,000 in 2020 to more than 275,000 in 2035.

  • Growing geriatric population is anticipated to drive the demand for haematology diagnostics

The global elderly population has been rising over the past years and is projected to further grow in the coming years as well. As the geriatric population ages, the risk of hematological disorders like anemia and leukemia increases. Regular haematological assessments are crucial for early detection and management.

Chronic diseases like cardiovascular diseases and diabetes also impact haematological parameters, making haematology diagnostics essential for monitoring their effects on blood composition and identifying associated complications. In the United States, the share of the elderly population aged 65 and above in the total population has increased from 12.98% in 2010 to 16.63% in 2020, as per the World Bank. China is another country witnessing a rapid rise in its geriatric population.

The population aged 65 and above reached 168.864 billion in the country in 2020, jumping from 108.012 billion in 2010, witnessing a growth of more than 36% over a decade. In France, the population aged 65 and above has surged from 10.958 billion in 2010 to 13.986 billion in 2020, growing by more than 27%. (Source: World Bank)

The population is anticipated to continue to age in the coming years, contributing significantly to the rise in the number of patients. This is anticipated to have a positive impact on the global haematology diagnostics market during the assessment period.

The North American region holds a significant market share

Geographically, the North American region is projected to hold a significant market share owing to the presence of diagnostic centers in abundance. Furthermore, an advanced healthcare system makes it simple for people to get their blood disorders diagnosed and consequently results in a significant market size of haematology diagnostics in the region.

The North American region is projected to witness substantial growth due to improved medical facilities leading to a higher number of people getting access to the needed healthcare services. The rising geriatric population and the overall population are other prominent reasons anticipated to propel the market growth of haematology diagnostics in this region during the forecast period.

North America's advanced healthcare infrastructure, high prevalence of haematological disorders, and rising incidence of chronic diseases drive demand for advanced haematology diagnostics. The region's focus on early diagnosis and monitoring of these conditions drives the demand for haematology diagnostics. Technological advancements in diagnostics, such as automated analyzers and molecular diagnostics, attract healthcare providers to invest in modern solutions. Point-of-care testing is also gaining popularity, contributing to market growth.

Key Developments:

  • February 2024- Sysmex Corporation and CellaVision entered a strategic alliance agreement to advance haematology solutions by expanding their portfolio, including next-generation cell morphology analyzers. The partnership began 20 years ago in the field of haematology, which analyzes red, white, and other blood cells. The agreement will extend until 2038 and will utilize Sysmex's expertise in enhancing efficiency and standardization of testing workflow in the haematology field, while maximizing synergies with CellaVision's digital imaging and analysis technologies. The goal is to enhance efficiency and standardization in the testing workflow and improve clinical value in supporting diagnoses.
  • August 2023- Abbott received FDA clearance for its Alinity h-series haematology system, allowing laboratories to run complete blood counts (CBC) as part of its Alinity family of diagnostic products. The system includes an automated haematology analyzer and an integrated slide maker and stainer. The Alinity h-series offers a wide array of tests doctors can use to quickly and effectively care for their patients. It offers advantages such as processing up to 119 CBC results per hour, requiring less floor space, and centralized results and control functions.
  • July 2023- Sysmex Europe SE introduced the XR-Series, its flagship product line for laboratory haematology. The line builds on the reliability and technology of its predecessor, the XN-Series. It offers new assets and improved throughput to meet laboratory needs. Launched in Japan, the XR-Series incorporates the strengths of customers worldwide. Haematology labs can automate barcode reading, tube sorting, smear management, and reagent management. President and CEO Alain Baverel aim to continue providing reliable diagnostics and services in haematology, stating that the XR-Series is a reliable option for labs.

Key Market Segmentation:

By Test Type

  • Hemoglobin
  • Blood Count
  • Platelet Function
  • Hematocrit
  • Others

By End-User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HAEMATOLOGY DIAGNOSTICS MARKET BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Hemoglobin
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Blood Count
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Platelet Function
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Hematocrit
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. HAEMATOLOGY DIAGNOSTICS MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Diagnostic Centers
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. HAEMATOLOGY DIAGNOSTICS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Test Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Test Type
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Test Type
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. UK
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Others
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Test Type
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Test Type
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. India
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. Japan
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Bio-Rad Laboratories, Inc.
  • 9.2. Boule Diagnostics AB
  • 9.3. Abbott Laboratories
  • 9.4. Diatron
  • 9.5. Biosystems S.A.
  • 9.6. F. Hoffmann-La Roche Ltd
  • 9.7. Horiba, Ltd.
  • 9.8. Erba Diagnostics Mannheim GmbH
  • 9.9. Ortho Clinical Diagnostics
  • 9.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.